መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ
በአሜሪካ ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ ተሳታፊዎችን እየፈለጉ ያሉ ክሊኒካዊ ጥናቶች
ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 120 ጥናቶች በአሜሪካ ውስጥ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በጣም ብዙ ጥናቶች ያሏቸው ከተሞች
- Boston, MA31 ጥናቶች
- Columbus, OH28 ጥናቶች
- Durham, NC27 ጥናቶች
- Washington, DC22 ጥናቶች
- Seattle, WA20 ጥናቶች
- Rochester, MN19 ጥናቶች
- New York City, NY18 ጥናቶች
- Houston, TX17 ጥናቶች
- Baldwin Park, CA16 ጥናቶች
- Milwaukee, WI15 ጥናቶች
- Chicago, IL14 ጥናቶች
- Cincinnati, OH14 ጥናቶች
- Nashville, TN13 ጥናቶች
- Jacksonville, FL11 ጥናቶች
- Philadelphia, PA11 ጥናቶች
- Atlanta, GA11 ጥናቶች
- Portland, OR10 ጥናቶች
- Dallas, TX10 ጥናቶች
- Salt Lake City, UT10 ጥናቶች
- Kansas City, MO10 ጥናቶች
- Pittsburgh, PA10 ጥናቶች
- San Diego, CA10 ጥናቶች
- Denver, CO9 ጥናቶች
- Charlotte, NC9 ጥናቶች
- Miami, FL9 ጥናቶች
- St. Louis, MO8 ጥናቶች
- Los Angeles, CA8 ጥናቶች
- Queens, NY8 ጥናቶች
- Omaha, NE8 ጥናቶች
- Winston-Salem, NC8 ጥናቶች
- Des Moines, IA8 ጥናቶች
- Tampa, FL8 ጥናቶች
- Cleveland, OH8 ጥናቶች
- Minneapolis, MN8 ጥናቶች
- Clifton, NJ7 ጥናቶች
- Aurora, CO7 ጥናቶች
- Cedar Rapids, IA7 ጥናቶች
- Mountain View, CA7 ጥናቶች
- Fort Wayne, IN7 ጥናቶች
- Detroit, MI7 ጥናቶች
በክልል
- New Jersey13 ጥናቶች
- New Mexico3 ጥናቶች
- New York26 ጥናቶች
- North Carolina34 ጥናቶች
- Ohio43 ጥናቶች
- Oklahoma4 ጥናቶች
- Oregon16 ጥናቶች
- Pennsylvania22 ጥናቶች
- Rhode Island6 ጥናቶች
- South Carolina5 ጥናቶች
- South Dakota3 ጥናቶች
- Tennessee17 ጥናቶች
- Texas38 ጥናቶች
- Utah10 ጥናቶች
- Virginia12 ጥናቶች
- Washington26 ጥናቶች
- Wisconsin19 ጥናቶች
- ሉዊዚያና6 ጥናቶች
- ሚሲሲፒ5 ጥናቶች
- ሚሺጋን12 ጥናቶች
- ሚኔሶታ29 ጥናቶች
- ሚዙሪ13 ጥናቶች
- ማሳቹሴትስ33 ጥናቶች
- ሜሪላንድ23 ጥናቶች
- ሜይን6 ጥናቶች
- ሞንታና7 ጥናቶች
- ኒብራስካ8 ጥናቶች
- ኒው ሃምፕሻየር3 ጥናቶች
- ኔቫዳ6 ጥናቶች
- አላባማ7 ጥናቶች
- አሪዞና15 ጥናቶች
- አርካንሳስ4 ጥናቶች
- አይዳሆ4 ጥናቶች
- አዮዋ10 ጥናቶች
- ኢሊኖይ17 ጥናቶች
- ኢንዲያና12 ጥናቶች
- ከንታኪ7 ጥናቶች
- ካሊፎርኒያ33 ጥናቶች
- ካንሳስ6 ጥናቶች
- ኮሎራዶ17 ጥናቶች
- ኮነቲከት4 ጥናቶች
- ዲስትሪክት ኦፍ ኮሎምቢያ4 ጥናቶች
- ዴላዌር4 ጥናቶች
- ጆርጂያ16 ጥናቶች
- ፍሎሪዳ34 ጥናቶች
በቅርብ ጊዜ የተዘመኑ ጥናቶች
Official study text (English)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 110 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05724121Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
ተሳታዮችን በመፈለግ ላይደረጃ 1
እስከ እድሜ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT07582432Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 75 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07685717A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06973187Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 110 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 85 · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT06136559Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT07648264ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።